CNTX is trading at $0.62 (5.1% down) as its multi-day rebound, fueled by positive CTIM-76 Phase 1 data and supportive analyst commentary, begins to fade.
- The stock is experiencing a pullback following significant volatility triggered by the June 15 collapse on ovarian cancer trial results.
- The decline appears to be a period of consolidation, as there are no new company-specific catalysts or major macroeconomic shocks reported today.